老年胶质母细胞瘤放疗联合替莫唑胺的真实世界报告
该研究连续纳入104例70岁及以上IDH野生型胶质母细胞瘤患者,接受不同放疗方案联合或不联合替莫唑胺治疗。结果显示联合替莫唑胺者生存优于单纯大分割放疗,MGMT启动子甲基化既非预后也非预测因素。
要点
- 老年胶质母细胞瘤患者接受放疗联合替莫唑胺较单纯大分割放疗生存更长。
- MGMT启动子甲基化状态在本队列中既非预后也非预测因素。
- 手术类型、RPA分级和替莫唑胺使用是总生存的独立预后因素。
核心结论
- 在真实世界老年胶质母细胞瘤队列中,放疗联合替莫唑胺较单纯大分割放疗显著延长生存,且不依赖MGMT状态。
研究设计与样本
- 2003至2016年连续纳入104例70岁及以上、病理诊断为IDH野生型胶质母细胞瘤并接受放疗的患者。
- 按治疗方案分为标准分割放疗联合替莫唑胺组33例、大分割放疗联合替莫唑胺组37例和大分割放疗 alone 组34例。
主要发现
- 全队列中位总生存为5.2个月,12、18和24个月生存率分别为19%、12%和5%。
- 标准分割联合替莫唑胺组与大分割联合替莫唑胺组的总生存无统计学差异(P=0.22)。
- 单纯大分割放疗组生存显著短于联合替莫唑胺组(3.9个月 vs. 5.9个月,P=0.018)。
- 多因素分析中手术类型(HR 0.47 [0.26-0.86],P=0.014)、RPA分级(HR 2.15 [1.17-3.95],P=0.014)和替莫唑胺使用(HR 0.54 [0.33-0.88],P<0.02)与总生存相关。
- MGMT启动子甲基化在33/73例(45%)中阳性,但既非预后也非预测因素。
临床怎么用
- 对70岁及以上IDH野生型胶质母细胞瘤患者,可考虑放疗联合替莫唑胺而不必依赖MGMT状态选择。
- 大分割放疗联合替莫唑胺可作为老年患者的标准治疗选择之一。
局限性
- 本研究为单中心回顾性真实世界队列,样本量有限,治疗分组非随机。
- 单纯大分割放疗组患者年龄更大且KPS更低,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The optimization of the management for elderly glioblastoma patients is crucial given the demographics of aging in many countries. We report the outcomes for a "real-life" patient cohort (i.e. unselected) comprising consecutive glioblastoma patients aged 70 years or more, treated with different radiotherapy +/- temozolomide regimens. METHODS: From 2003 to 2016, 104 patients ≥ 70 years of age, consecutively treated by radiotherapy for glioblastoma, were included in this study. All patients were diagnosed with IDH-wild type glioblastoma according to pathological criteria. RESULTS: Our patient cohort comprised 51 female patients (49%) and 53 male. The median cohort age was 75 years (70-88), and the median Karnofsky performance status (KPS) was 70 (30-100). Five (5%) patients underwent macroscopic complete resection, 9 (9%) had partial resection, and 90 (86%), a stereotactic biopsy. The MGMT promoter was methylated in 33/73 cases (45%). Fifty-two (50%), 38 (36%), and 14 (14%) patients were categorized with RPA scores of III, IV, and I-II. Thirty-three (32%) patients received normofractionated radiotherapy (60 Gy, 30 sessions) with temozolomide (Stupp), 37 (35%) received hypofractionated radiotherapy (median dose 40 Gy, 15 sessions) with temozolomide (HFRT + TMZ), and 34 (33%) HFRT alone. Patients receiving only HFRT were significantly older, with lower KPSs. The median overall survival (OS; all patients) was 5.2 months. OS rates at 12, 18, and 24 months, were 19%, 12%, and 5%, respectively, with no statistical differences between patients receiving Stupp or HFRT + TMZ (P = 0.22). In contrast, patients receiving HFRT alone manifested a significantly shorter survival time (3.9 months vs. 5.9 months, P = 0.018). In multivariate analyses, the prognostic factors for OS were: i) the type of surgery (HR: 0.47 [0.26-0.86], P = 0.014), ii) RPA class (HR: 2.15 [1.17-3.95], P = 0.014), and iii) temozolomide use irrespective of radiotherapy schedule (HR: 0.54 [0.33-0.88], P < 0.02). MGMT promoter methylation was neither a prognostic nor a predictive factor. CONCLUSIONS: These outcomes agree with the literature in terms of optimal surgery and the use of HFRT as a standard treatment for elderly GBM patients. Our study emphasizes the potential benefit of using temozolomide with radiotherapy in a real-life cohort of elderly GBM patients, irrespective of their MGMT status.
引用
- Biau J, Chautard E, De Schlichting E, et al. Radiotherapy plus temozolomide in elderly patients with glioblastoma: a "real-life" report. Radiat Oncol. 2017. PMID: 29212499. doi:10.1186/s13014-017-0929-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。